GET DAILY SIGNALSAgenus (AGEN) Posts Q3 Revenue Beat, Achieves Operating Profitability Again, and Lands First Regulatory Approvals
Key Takeaways
- Agenus reported $31.5 million in total revenue for the third quarter of 2026, up 4.3% year over year and above the roughly $28.2 million consensus estimate.
- The company posted net income of $2.8 million and operating income of $11.4 million, marking its third consecutive quarter of positive operating income.
- Cash, cash equivalents, and short-term investments surged to $86.9 million as of September 30, 2026, from $18.7 million three months earlier, driven by an oversubscribed private placement.
- Agenus secured its first-ever marketing authorizations, winning conditional approvals in Armenia for the BOT+BAL combination in a form of metastatic colorectal cancer.
- The company is advancing its Phase 3 ROBBIN trial, targeting first patient enrollment in the first quarter of 2027.
- For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated analysis pages.
- Interested in automated strategies? Browse Trending AI Robots to see how AI-driven trading tools approach opportunities like this one.
Why This Quarter Stands Out
AGEN is a clinical-stage immuno-oncology company whose lead program pairs botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody. The third-quarter update matters because it shows whether the recent shift to operating profitability can hold, especially after cash concerns had been front and center for investors. The July private placement gave the first real look at the post-financing balance sheet, and the results arrived alongside the first regulatory nods for the BOT+BAL combination anywhere, which could change how the commercial opportunity is viewed even while U.S. approval is still pending. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Reported Figures
For the third quarter of 2026, ended September 30, 2026, AGEN reported total revenue of $31.5 million, up from $30.2 million in the same period a year earlier and ahead of the roughly $28.2 million consensus estimate. Revenue included $6.0 million in pre-commercial product sales of the BOT+BAL combination and $25.5 million in non-cash royalty revenue, which does not generate cash for the company.
The company posted operating income of $11.4 million, compared with an operating loss of $4.6 million a year earlier, representing a third consecutive quarter of positive operating income. Net income was $2.8 million for the quarter, bringing net income for the first nine months of 2026 to $41.4 million.
On the balance sheet, cash, cash equivalents, and short-term investments climbed to $86.9 million at September 30, 2026, up from $18.7 million at June 30, 2026. The increase reflected an oversubscribed private placement completed in July that delivered roughly $85 million in upfront gross proceeds, with milestone-aligned warrants offering up to approximately $255 million in additional proceeds if fully exercised.
Market Reaction and Investor Sentiment
Heading into the report, sentiment around AGEN had improved significantly, with the stock up sharply on a trailing 12-month basis as investors began pricing in the company's move toward sustained profitability and a stronger balance sheet. The quarter's revenue beat and third consecutive period of positive operating income reinforced that narrative, while the sharp rise in cash eased a key overhang that had weighed on the shares. At the same time, investors remain mindful that a substantial portion of reported revenue is non-cash royalty income, meaning top-line figures do not translate directly into operating cash flow. The Armenia approvals added a positive regulatory catalyst, though the conditional, one-year nature of those authorizations and the absence of U.S. Food and Drug Administration (FDA) approval leave the near-term commercial story concentrated outside the United States.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important catalyst is the Phase 3 ROBBIN trial, which Agenus expects to begin enrolling its first patients in the first quarter of 2027. This registrational study is designed to enroll roughly 850 patients and will be central to the company's pursuit of U.S. approval for the BOT+BAL combination in microsatellite-stable (MSS) metastatic colorectal cancer. From what I see, tracking how the early approvals translate into broader international strategy will also be important, given their conditional and renewable nature.
Finally, cash discipline remains a focal point. While the July private placement strengthened the balance sheet and management has indicated resources may support operations into late 2027 and potentially beyond, the pace of spending on the ROBBIN program and other pipeline efforts will determine how far that runway ultimately extends. As always, the mix of cash-generating product revenue versus non-cash royalty revenue will shape how investors interpret future quarterly results.
Using Tickeron AI Tools in My Research
In my analysis, I often turn to Tickeron’s AI Screener to quickly identify comparable biotech names and emerging signals. It helps filter based on fundamentals, technical patterns, and performance metrics more efficiently than manual screening. This tool has become a regular part of how I evaluate setups like the one unfolding at Agenus, especially when scanning across the sector for similar opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AGEN in -7.90% downward trend, falling for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AGEN declined for three days, in 284 of 316 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 49 cases where AGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
AGEN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AGEN crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AGEN's RSI Oscillator exited the oversold zone, 33 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AGEN as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for AGEN just turned positive on October 29, 2026. Looking at past instances where AGEN's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGEN advanced for three days, in 219 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 65 of 94 cases where AGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. AGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.461) is normal, around the industry mean (2.904). P/E Ratio (2.147) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (1.994) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technologies to treat cancers and infectious diseases
Industry Biotechnology
Advertisement